Table 3.

Baseline and follow-up clinical characteristics of HIV-positive adults receiving ART in Felegehiwot comprehensive Hospital, 2023 (N = 404).

Variable	Category	Frequency	%
Baseline TB/HIV co-infection	Yes	94	23.27
	No	310	76.73
Presence of OIs	Yes	175	43.32
	No	229	56.68
Baseline CD4 level	> 500 cell/mm3	103	25.50
	200–500 cell/mm3	188	46.53
	< 200 cells/mm3	113	27.97
Baseline WHO clinical staging	WHO stage I/II	221	54.70
	WHO stage III/IV	183	45.30
Chronic diseases	Yes	41	10.15
	No	363	363
Functional status	Working	307	75.99
	Ambulatory/bedridden	97	24.01
IPT utilization	Yes	226	55.94
	No	178	44.06
CPT utilization	Yes	237	58.66
	No	167	41.34
ART drug Adherence	Good adherence	226	55.94
	Fair/poor adherence	178	44.06
Disclosure status	Yes	255	63.12
	No	149	36.88
ART initiation time	Early	221	54.70
	Late	183	45.30
Baseline ART regimen	TDF/3TC/EFV	254	62.87
	TDF/3TC/DTG	111	27.48
	Others	39	9.65
ART drug side effect	Yes	43	10.64
	No	361	89.36
History of treatment failure	Yes	18	4.46
	No	386	95.54

OIs opportunistic infection other than TB, CPT cotrimoxazole preventive therapy, IPT isoniazid preventive therapy, Others include AZT/3TC/NVP ART regimen, TDF/3TC/NVP, ART regimen, AZT/3TC/EFV ART regimen…